Cargando…
Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity
Background: Liraglutide is a once-daily injectable medication approved for the treatment of obesity. Hereby we report the feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity. Methods and Sample: Twenty-nine patients with Bipolar or...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351474/ https://www.ncbi.nlm.nih.gov/pubmed/30728788 http://dx.doi.org/10.3389/fpsyt.2018.00784 |
_version_ | 1783390577656594432 |
---|---|
author | Cuomo, Alessandro Bolognesi, Simone Goracci, Arianna Ciuoli, Cristina Beccarini Crescenzi, Bruno Maina, Giuseppe Rosso, Gianluca Facchi, Edvige Maccora, Carla Giordano, Nicola Verdino, Valeria Fagiolini, Andrea |
author_facet | Cuomo, Alessandro Bolognesi, Simone Goracci, Arianna Ciuoli, Cristina Beccarini Crescenzi, Bruno Maina, Giuseppe Rosso, Gianluca Facchi, Edvige Maccora, Carla Giordano, Nicola Verdino, Valeria Fagiolini, Andrea |
author_sort | Cuomo, Alessandro |
collection | PubMed |
description | Background: Liraglutide is a once-daily injectable medication approved for the treatment of obesity. Hereby we report the feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity. Methods and Sample: Twenty-nine patients with Bipolar or Major Depressive Disorder received liraglutide once daily subcutaneously at a dose gradually titrated from 0.6 to 3 mg. All patients were obese and had previously failed multiple healthy lifestyle interventions, including exercise and diet programs. Patients' weight was recorded before liraglutide treatment (T0) and then 1 (T1), 3 (T3), and 6 months (T6) following T0. Results: Mean baseline (T0) weight was 110.54 Kg (±24.95). Compared to baseline, the percentage of weight loss was 3.37% at T1, 7.85% at T3, and 10.20% at T6. Thirty-one percent (n = 9) of patients had no side effects, 34.48% (n = 10) had one, 24.14% (n = 7) had two, and 10.34% (n = 3) had three side effects. All 29 subjects were still on liraglutide at T1; 79.31 and 48.28% were on liraglutide at T3 and T6. No significant relationship was found between liraglutide dose and likelihood to continue the medication. No patient showed a worsening of the psychiatric condition due to liraglutide treatment. Acceptability and satisfaction with treatment were good for the 48% that completed the study. Conclusions: Liraglutide treatment was efficacious, accepted and tolerated by ~50% of our sample, followed up for a period of 180 days. Larger, longer, controlled, prospective studies are warranted. |
format | Online Article Text |
id | pubmed-6351474 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63514742019-02-06 Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity Cuomo, Alessandro Bolognesi, Simone Goracci, Arianna Ciuoli, Cristina Beccarini Crescenzi, Bruno Maina, Giuseppe Rosso, Gianluca Facchi, Edvige Maccora, Carla Giordano, Nicola Verdino, Valeria Fagiolini, Andrea Front Psychiatry Psychiatry Background: Liraglutide is a once-daily injectable medication approved for the treatment of obesity. Hereby we report the feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity. Methods and Sample: Twenty-nine patients with Bipolar or Major Depressive Disorder received liraglutide once daily subcutaneously at a dose gradually titrated from 0.6 to 3 mg. All patients were obese and had previously failed multiple healthy lifestyle interventions, including exercise and diet programs. Patients' weight was recorded before liraglutide treatment (T0) and then 1 (T1), 3 (T3), and 6 months (T6) following T0. Results: Mean baseline (T0) weight was 110.54 Kg (±24.95). Compared to baseline, the percentage of weight loss was 3.37% at T1, 7.85% at T3, and 10.20% at T6. Thirty-one percent (n = 9) of patients had no side effects, 34.48% (n = 10) had one, 24.14% (n = 7) had two, and 10.34% (n = 3) had three side effects. All 29 subjects were still on liraglutide at T1; 79.31 and 48.28% were on liraglutide at T3 and T6. No significant relationship was found between liraglutide dose and likelihood to continue the medication. No patient showed a worsening of the psychiatric condition due to liraglutide treatment. Acceptability and satisfaction with treatment were good for the 48% that completed the study. Conclusions: Liraglutide treatment was efficacious, accepted and tolerated by ~50% of our sample, followed up for a period of 180 days. Larger, longer, controlled, prospective studies are warranted. Frontiers Media S.A. 2019-01-23 /pmc/articles/PMC6351474/ /pubmed/30728788 http://dx.doi.org/10.3389/fpsyt.2018.00784 Text en Copyright © 2019 Cuomo, Bolognesi, Goracci, Ciuoli, Beccarini Crescenzi, Maina, Rosso, Facchi, Maccora, Giordano, Verdino and Fagiolini. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry Cuomo, Alessandro Bolognesi, Simone Goracci, Arianna Ciuoli, Cristina Beccarini Crescenzi, Bruno Maina, Giuseppe Rosso, Gianluca Facchi, Edvige Maccora, Carla Giordano, Nicola Verdino, Valeria Fagiolini, Andrea Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity |
title | Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity |
title_full | Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity |
title_fullStr | Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity |
title_full_unstemmed | Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity |
title_short | Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity |
title_sort | feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6351474/ https://www.ncbi.nlm.nih.gov/pubmed/30728788 http://dx.doi.org/10.3389/fpsyt.2018.00784 |
work_keys_str_mv | AT cuomoalessandro feasibilityadherenceandefficacyofliraglutidetreatmentinasampleofindividualswithmooddisordersandobesity AT bolognesisimone feasibilityadherenceandefficacyofliraglutidetreatmentinasampleofindividualswithmooddisordersandobesity AT goracciarianna feasibilityadherenceandefficacyofliraglutidetreatmentinasampleofindividualswithmooddisordersandobesity AT ciuolicristina feasibilityadherenceandefficacyofliraglutidetreatmentinasampleofindividualswithmooddisordersandobesity AT beccarinicrescenzibruno feasibilityadherenceandefficacyofliraglutidetreatmentinasampleofindividualswithmooddisordersandobesity AT mainagiuseppe feasibilityadherenceandefficacyofliraglutidetreatmentinasampleofindividualswithmooddisordersandobesity AT rossogianluca feasibilityadherenceandefficacyofliraglutidetreatmentinasampleofindividualswithmooddisordersandobesity AT facchiedvige feasibilityadherenceandefficacyofliraglutidetreatmentinasampleofindividualswithmooddisordersandobesity AT maccoracarla feasibilityadherenceandefficacyofliraglutidetreatmentinasampleofindividualswithmooddisordersandobesity AT giordanonicola feasibilityadherenceandefficacyofliraglutidetreatmentinasampleofindividualswithmooddisordersandobesity AT verdinovaleria feasibilityadherenceandefficacyofliraglutidetreatmentinasampleofindividualswithmooddisordersandobesity AT fagioliniandrea feasibilityadherenceandefficacyofliraglutidetreatmentinasampleofindividualswithmooddisordersandobesity |